Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Kamada Ltd. (NASDAQ: KMDA).

Full DD Report for KMDA

You must become a subscriber to view this report.


Recent News from (NASDAQ: KMDA)

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2018 Financial Results and Host Conference Call on November 12
REHOVOT, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the third quarter and nine months ended September 30, 2018, prior to the open of the U.S. finan...
Source: GlobeNewswire
Date: November, 05 2018 07:00
Kamada extends collaboration with Massachusetts General Hospital
Kamada Ltd. (NASDAQ: KMDA ) extends collaboration with Massachusetts General Hospital for a proof-of-concept study evaluating the potential benefit of the Company’s liquid Alpha-1 Antitrypsin (AAT) on liver preservation and transplant rejection prevention. More news on: ...
Source: SeekingAlpha
Date: September, 05 2018 07:54
Kamada Announces Extension of Collaboration with Massachusetts General Hospital for a Proof-of-Concept Study Evaluating the Potential Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation
REHOVOT, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (the "Company") (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced the extension of an ongoing investigator initiated, proof-of-concept study evaluating the potential benefit of the Compan...
Source: GlobeNewswire
Date: September, 05 2018 07:00
Kamada Provides Updated Full-Year 2018 Revenue Guidance
As result of the recent labor strike part of 2018 shipments are likely to be delayed to early 2019 Subsequent update and full-year 2019 revenue guidance to be provided later this year REHOVOT, Israel, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a pla...
Source: GlobeNewswire
Date: August, 29 2018 07:00
Cannabics Pharmaceuticals Inc. Appoints Dr. Estery Giloz-Ran to Its Advisory Board
TEL AVIV, Israel , August 28, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, Board of Directors is proud to announce its addition of Dr Giloz-Ran, former manager of Grants Capital...
Source: PR Newswire
Date: August, 28 2018 13:02
Kamada Announces the End of the Labor Strike in the Company's Manufacturing Facility; All Employees Returned to Work
REHOVOT, Israel, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a plasma-derived protein therapeutics company, today announced that on August 15, 2018, the Company, the Employees’ Committee of Kamada’s Beit Kama production facility in Israel (the ...
Source: GlobeNewswire
Date: August, 16 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-146.056.156.206.0516,300
2017-02-036.506.606.706.5018,892
2017-02-026.506.456.506.407,907
2017-02-016.306.406.406.27529,052
2017-01-316.056.24346.256.054,333

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-141021,4057.2598Cover
2018-12-1372,7070.2586Cover
2018-12-1287111.1252Cover
2018-12-113002,30113.0378Cover
2018-12-101,4492,99048.4615Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on KMDA.


About Kamada Ltd. (NASDAQ: KMDA)

Logo for Kamada Ltd. (NASDAQ: KMDA)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $195,274,672 - 05/17/2018
  • Issue and Outstanding: 40,262,819 - 12/31/2017

 


Recent Filings from (NASDAQ: KMDA)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: September, 05 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 29 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 16 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 26 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: July, 10 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: June, 04 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 09 2018

 

 


Daily Technical Chart for (NASDAQ: KMDA)

Daily Technical Chart for (NASDAQ: KMDA)


Stay tuned for daily updates and more on (NASDAQ: KMDA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: KMDA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in KMDA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of KMDA and does not buy, sell, or trade any shares of KMDA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/